The biotechnology company Moderna’s protocol files for Covid-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida, on August 13, 2020. | Chandan Khanna/AFP via Getty Images

The company is now seeking Food and Drug Administration approval.

With the already staggering coronavirus case and death toll expected to climb further in the US following Thanksgiving, there’s at least more good news on the vaccine front. The biotech firm Moderna released the final results of its 30,000-person vaccine trial in a press release Monday, reporting a 94.1 percent rate of efficacy. The finding squares with the 94.5 percent efficacy rate the company reported two weeks ago, based on its first interim analysis of trial data.

Of the 196 Covid-19 cases in the trial, 185 were in the placebo group and only 11 in the vaccine group, Moderna reported.